46P - Activity of IAP antagonist Debio 1143 as a monotherapy and in combination with standard of care agents in models of human lung cancer of different h...

Date 28 March 2014
Event ELCC 2014
Session Lunch and poster display session
Topics Basic Science
Lung and other Thoracic Tumours
Translational Research
Presenter Norbert Wiedemann
Citation Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131
Authors N. Wiedemann1, C.G. Langdon2, M.A. Held2, J.T. Platt2, C. Zanna3, M. Sorensen4, S. Wang5, M.W. Bosenberg2, D.F. Stern2, G. Vuagniaux1
  • 1Pharmacology & Screening, Debiopharm International S.A., 1002 - Lausanne/CH
  • 2School Of Medicine, Yale University, 06510 - New Haven/US
  • 3Medical Affairs, Debiopharm International S.A., 1002 - Lausanne/CH
  • 4R&d, Ascenta Therapeutics, 19355 - Malvern/US
  • 5Internal Medicine And Pharmacology, Medicinal Chemistry, Michigan University, 48109-0934 - Ann Arbor/US


Drug resistance is a major problem in cancer therapy and response to therapy varies between histotypes and within the same histotype. Resistance may be overcome by the combination of drugs simultaneously targeting multiple critical nodes of the signalling networks controlling growth and survival of cancer cells. The members of the Inhibitor of apoptosis protein (IAP) family are frequently overexpressed in most cancer types contributing to tumour cell survival and resistance to cancer therapy. The oral monovalent IAP inhibitor Debio 1143/AT-406 is currently in clinical development for cancer treatment. The aim of the study was to evaluate the activity of Debio 1143 as a single agent and in drug combinations in in vitro and in vivo lung cancer models of different histotypes.